These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 37298276)

  • 1. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
    Lee HA; Kim HY
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C; Cusi K; Kadiyala S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
    Tsiampali C; Papaioannidou P; Goulas A; Polyzos SA
    Expert Rev Clin Pharmacol; 2023; 16(11):1063-1072. PubMed ID: 37864548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L; Li J; Zeng H; Liu J
    Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
    Barritt AS; Marshman E; Noureddin M
    Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
    Soresi M; Giannitrapani L
    World J Gastroenterol; 2024 Aug; 30(30):3541-3547. PubMed ID: 39193573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
    Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
    Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.
    Gu Y; Sun L; He Y; Yang L; Deng C; Zhou R; Kong T; Zhang W; Chen Y; Li J; Shi J
    Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):273-282. PubMed ID: 36689199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Abdelmalek MF; Harrison SA; Sanyal AJ
    Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
    Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA
    Obes Rev; 2024 Mar; 25(3):e13663. PubMed ID: 37968541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
    J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.
    Jiang H; Zang L
    Curr Pharm Des; 2024; 30(2):100-114. PubMed ID: 38532322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
    Wang XC; Gusdon AM; Liu H; Qu S
    World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.